Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.

Eli Lilly and Company LLY will report its fourth ... Sales of the new Alzheimer’s drug Kisunla (donanemab) are likely to have been much higher than the third-quarter number of $1.4 million.

An international clinical trial aimed at preventing Alzheimer’s disease (AD) in young adults who are at risk of developing ...

The first participants in an international clinical trial aimed at preventing Alzheimer’s disease in young adults at high ...

Last month, the FDA granted approval to Eli Lilly’s donanemab - or Kisunla - for the treatment of Alzheimer’s disease. Its approval was based on the treatment demonstrating what the FDA ...